Jpmorgan Chase & CO Unicycive Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding UNCY
# of Institutions
25Shares Held
17.4MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA3.47MShares$1.46 Million0.26% of portfolio
-
Logos Global Management LP San Francisco, CA3.47MShares$1.46 Million0.16% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.82MShares$1.18 Million0.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.63MShares$1.11 Million0.02% of portfolio
-
Bvf Inc San Francisco, CA2.2MShares$924,0000.03% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $6.32M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...